Disrupted mucosal immunity to glycoprotein 2 isoform 1 as a novel diagnostic biomarker for cholangiocarcinoma
Zeitschrift für Gastroenterologie · 01.09.2024 · 62 (09) · e739-e740
DOI: 10.1055/s-0044-1789920 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.09.2024. Verfasst von M. Krawczyk und 17 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Cholangiocarcinoma (CCA) is an exceptionally aggressive tumor with poor outcomes. In our previous studies, we demonstrated that anti-glycoprotein 2 (anti-GP2) IgA and antineutrophil-cytoplasmic antibodies to proteinase 3 (PR3-ANCA) represent predictive markers of CCA in primary sclerosing cholangitis (PSC) patients. Here we investigate these antibodies in two independent cohorts of patients with CCA without underlying PSC and in patients with hepatic and pancreatic tumors.
Methods
We analysed two separate groups of patients with CCA without PSC: Asian discovery (n=118) and European validation (n=38) cohorts. We also recruited 49 Asian and 82 European pancreatic ductal adenocarcinoma (PDAC) patients, 21 with benign pancreatic neoplasms (BPN) and 45 with hepatocellular carcinoma (HCC), as well as 157 healthy controls (HC) from Asia and Europe. We evaluated the presence of PR3-ANCA, IgA and IgG against GP2 1 and GP2 4 , along with the CA19-9 levels.
Results
Anti-GP2 1 IgA was the most prevalent autoantibody in both CCA cohorts, detected in 55.1% of the discovery cohort and in 42.1% of the validation cohort, significantly more frequent than in other groups (all p < 0.05) except PDAC. This antibody also showed superior diagnostic efficacy in differentiating CCA from other diseases and healthy controls, surpassing traditonal tumor marker. No significant association was found between anti-GP2 1 IgA levels and CA19-9 levels.
Conclusion
The prevalence of anti-GP21 IgA in CCA patients highlights its potential as a marker differentiating CCA from other hepatobiliary conditions such hepatocellular carcinoma and benign pancreatic neoplasms. This underscores a possible mucosal immune response disruption in CCA. Publication History Article published online: 26 September 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Krawczyk, M., Xia, C., Di, C., Krupa, Ł., Kruk, B., Krawczyk, P., Mikiewicz, P., Bao, H., He, X., Liu, D., Fan, C., Nasser, A., Lopens, S., Weiss, F. U., Frost, F., Schierack, P., Roggenbuck, D., & Liu, Y. (2024). Disrupted mucosal immunity to glycoprotein 2 isoform 1 as a novel diagnostic biomarker for cholangiocarcinoma. Zeitschrift für Gastroenterologie, 62(09), e739-e740. https://doi.org/10.1055/s-0044-1789920
Vancouver
Krawczyk M, Xia C, Di C, Krupa Ł, Kruk B, Krawczyk P, et al. Disrupted mucosal immunity to glycoprotein 2 isoform 1 as a novel diagnostic biomarker for cholangiocarcinoma. Zeitschrift für Gastroenterologie. 2024;62(09):e739-e740. doi:10.1055/s-0044-1789920
BibTeX
@article{Krawczyk2024,
author = {Krawczyk, M. and Xia, C.-S. and Di, C. and Krupa, Ł. and Kruk, B. and Krawczyk, P. and Mikiewicz, P. and Bao, H. and He, X. and Liu, D. and Fan, C. and Nasser, A. and Lopens, S. and Weiss, F. U. and Frost, F. and Schierack, P. and Roggenbuck, D. and Liu, Y.},
title = {Disrupted mucosal immunity to glycoprotein 2 isoform 1 as a novel diagnostic biomarker for cholangiocarcinoma},
journal = {Zeitschrift für Gastroenterologie},
year = {2024},
volume = {62},
number = {09},
pages = {e739--e740},
doi = {10.1055/s-0044-1789920}
}
EUVIMED